FIRST AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research
THIS FIRST AMENDMENT is entered into as of this 28th day of June, 2013 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation (“Intrexon”) and Fibrocell Science, Inc. (“Fibrocell”), on October 5, 2012 (the “Agreement”). All capitalized terms not defined herein shall have the meaning set forth in the Agreement.
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of October 5, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and FIBROCELL SCIENCE, INC., a Delaware corporation having its principal place of business at 405 Eagleview Boulevard, Exton, PA 19341 (“Fibrocell”). Intrexon and Fibrocell may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of June 5, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 3000 Bayport Drive, Suite 685, Tampa, FL 33607 (“Oragenics”). Intrexon and Oragenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of August 6, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and SYNTHETIC BIOLOGICS, INC., a Nevada corporation having its principal place of business at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104 (“Synthetic”). Intrexon and Synthetic may be referred to herein individually as a “Party”, and collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of June 6, 2011 (the “Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and INTREXON CORPORATION, a Virginia corporation (“Intrexon”).
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and AMPLIPHI BIOSCIENCES CORPORATION, a Washington corporation having a place of business at 800 E. Leigh St., Suite 54, Richmond, VA, 23219 (“Ampliphi”). Intrexon and Ampliphi may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of November 28, 2011 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, Maryland 20876 (“Intrexon”), and ELANCO ANIMAL HEALTH, a division of Eli Lilly and Company, and its Affiliates, having its principal place of business at 2500 Innovation Way, Greenfield, Indiana 46140 (collectively “Elanco”). Intrexon and Elanco may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of April 27, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and SOLIGENIX, INC., a Delaware corporation having a place of business at 29 Emmons Drive, Suite C-10, Princeton, NJ 08540 (“Soligenix”). Intrexon and Soligenix may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and GENOPAVER, LLC, a Delaware limited liability company having a place of business at 2875 South Ocean Boulevard, Suite 214, Palm Beach, FL 33480 (“Genopaver”). Intrexon and Genopaver may be referred to herein individually as a “Party”, and collectively as the “Parties.”
ContractRelationship Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS RELATIONSHIP AGREEMENT (this “Agreement”) is made on 2012 by and between Intrexon Corporation, incorporated in Virginia, USA, with offices at [ ] (“Intrexon”), and AquaBounty Technologies, Inc., incorporated in Delaware, USA, with offices atx 935 Main Street, Waltham, Mass 02451, USA (the “Company”).
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of February 14, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and AQUABOUNTY TECHNOLOGIES, INC., a Delaware corporation having its principal place of business at Two Clock Tower Place, Suite 395, Maynard, MA 01754 (“AquaBounty”). Intrexon and AquaBounty may be referred to herein individually as a “Party”, and collectively as the “Parties.”
STOCK PURCHASE AGREEMENTStock Purchase Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS AGREEMENT (“Agreement”) is made and entered into as of January 6, 2011 (the “Effective Date”), by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the “Company”), and Intrexon Corporation, a Virginia corporation (“Intrexon”).
EXCLUSIVE CHANNEL PARTNER AGREEMENTExclusive Channel Partner Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • New York
THIS EXCLUSIVE CHANNEL PARTNER AGREEMENT (the “Agreement”) is made and entered into effective as of January 6, 2011 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ZIOPHARM ONCOLOGY, INC., a Delaware corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 9th, 2013 • Intrexon Corp • Services-commercial physical & biological research • Virginia
THIS EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (as amended from time to time, this “Agreement”) is made as of this 1st day of March, 2013 among Intrexon Corporation, a Virginia corporation (the “Company”), the Series Preferred Shareholders (as defined below) and certain holders of common stock of the Company (the “Existing Shareholders”), and each other Holder (as defined below) who hereafter executes a joinder or counterpart signature page hereto and agrees to be bound by the terms hereof.
